Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Robert J. Lipsy is active.

Publication


Featured researches published by Robert J. Lipsy.


Annals of Pharmacotherapy | 1991

Adverse Effects and Drug Interactions Associated with Fluoxetine Therapy

Edward A. Hartshorn; Miriam L. Levinson; Robert J. Lipsy; Dennis K. Fuller

Fluoxetine, an inhibitor of serotonin reuptake, was released by the Food and Drug Administration in 1988 and was among the most prescribed drugs for that year. Although fluoxetine has been promoted as a safe antidepressant, a recent literature search revealed a number of case reports of adverse effects and drug interactions attributed to its use. This review familiarizes healthcare professionals with some of the currently known interactions and adverse effects and suggests ways of avoiding such events in clinical practice.


Pharmacotherapy | 1995

Hemodynamic effects of intravenous famotidine in critically ill patients.

Robert J. Lipsy; Collin D. Freeman

Study Objective: To study the hemodynamic effects of famotidine administered undiluted intravenously over 2 minutes.


Journal of Pharmacy Practice | 1994

Adverse Gastrointestinal Effects of Nonsteroidal Anti-Inflammatory Drugs

Brian L. Erstad; Robert J. Lipsy

There are a substantial number of adverse reactions attributable to nonsteroidal anti-inflammatory drug (NSAID) therapy, particularly of the gastrointestinal (GI) tract. The stomach is most commonly affected, although injury may occur from esophagus to colon. The incidence of developing serious GI toxicity seems to be three times as great in users compared with nonusers of NSAIDs. Age greater than 60 years, history of GI problems, previous corticosteroid use, and recency of NSAID use seem to increase the risk of toxicity. Short-term studies have found differences in ulceration or bleeding caused by various NSAIDs. However, there are insufficient long-term clinical trials involving adequate numbers of patients to demonstrate substantial advantages for any particular NSAID based on its toxicity profile. Prostaglandin inhibition seems to be one mechanism responsible for the GI toxicity of NSAIDs, but it is probably not the only mechanism. When serious GI bleeding occurs, the NSAID use must be stopped, although omeprazole and misoprostol have been used successfully to treat gastroduodenal ulcerations in patients while continuing NSAID therapy. Misoprostol and possibly omeprazole have effectively prevented GI ulceration associated with NSAID therapy, but questions remain regarding patient selection, length of therapy, and their utility in preventing serious GI bleeding. At this time, routine prophylaxis for patients receiving long-term NSAID therapy cannot be recommended.


Journal of Managed Care Pharmacy | 2003

The National Cholesterol Education Program Adult Treatment Panel III guidelines.

Robert J. Lipsy


JAMA Internal Medicine | 1990

Clinical Review of Histamine2 Receptor Antagonists

Robert J. Lipsy; Brian Fennerty; Timothy C. Fagan


Annals of Pharmacotherapy | 1993

Design, Implementation, and Use of a New Antimicrobial Order Form: A Descriptive Report

Robert J. Lipsy; Gary H. Smith; Marie E. Maloney


The American Journal of Managed Care | 2010

Will the Newer Oral MS Agents Be Welcomed by Managed Care Organizations

Robert J. Lipsy; PharmD; Fashp; Bcps


The American Journal of Managed Care | 2008

Assessing the short-term and long-term burden of illness in cervical cancer.

Robert J. Lipsy


Journal of Managed Care Pharmacy | 2015

Current and future directions in MS management: key considerations for managed care pharmacists.

Robert J. Lipsy; Randall T. Schapiro; Chris R. Prostko


Journal of Managed Care Pharmacy | 2004

Anticipating the Future: How the Emergence of Innovative Biologic Agents Impacts Benefit Design, Utilization, and Provider Relations

Robert J. Lipsy; Mark G. Fuller; Joachim Roski; Sharad Mansukani

Collaboration


Dive into the Robert J. Lipsy's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Edward A. Hartshorn

University of Texas at San Antonio

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge